ArticleBMJ oncology2024

Preclinical study and parallel phase II trial evaluating antisense STAT3 oligonucleotide and checkpoint blockade for advanced pancreatic, non-small cell lung cancer and mismatch repair-deficient colorectal cancer.

Chad Tang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.